Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock

investors.com/news/technology/replimune-stock-surprise-fda-rejection-melanoma-treatment

Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma treatment.
The post Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock appeared first on Investor's Business Daily.

This story appeared on investors.com, 2025-07-22 17:29:40.
The Entire Business World on a Single Page. Free to Use →